As discussed above, both the WHO-HAEM5 and ICC have softened the blast requirement for most genetic subtypes of AML (Table 6), with the exception of BCR::ABL1 fusion: cases with BCR::ABL1 and 10–19% blasts are still considered within the category of CML (accelerated phase in the ICC). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.